Vasandani V M, Wu Y N, Mikulski S M, Youle R J, Sung C
Biochemistry Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland 20892, USA.
Cancer Res. 1996 Sep 15;56(18):4180-6.
The similarities and differences among members of the RNase A superfamily provide an ideal opportunity to examine the molecular basis for differences in their pharmacokinetics and biodistribution. Plasma clearances in BALB/c mice are similar among the five RNases studied: human pancreatic RNase, angiogenin, eosinophil-derived neurotoxin, onconase, and bovine seminal RNase. The average clearance is 0.13 ml/min or 60% of the glomerular filtration rate (measured by [14C]inulin clearance during continuous infusion from an i.p. implanted osmotic pump). Angiogenin has a higher volume of distribution and plasma-to-muscle transport rate than the other RNases, suggestive of binding to endothelial cells. Organ distribution differs dramatically among these RNases. The RNase most toxic to tumor cells, onconase, exhibits the longest retention in the kidneys: at 180 min, 50% of the injected dose is found in the kidneys, whereas only 1% or less of the other RNases is retained in the kidneys. Slower elimination of onconase from the kidneys may be due to a higher degree of binding in the kidney or a resistance to proteolytic degradation. To elucidate the molecular determinants involved in tissue uptake, we examined the biodistribution of recombinant onconase and two onconasepancreatic RNase chimeric proteins. The tissue retention property of onconase appears to be located in at least two regions, one of which is in the NH2-terminal 9-amino acid alpha-helix. The NH2-terminal pyroglutamate of onconase, a residue essential for ribonucleolytic activity and cytotoxicity, does not play a role in kidney retention.
核糖核酸酶A超家族成员之间的异同,为研究它们在药代动力学和生物分布方面存在差异的分子基础提供了一个理想的机会。在BALB/c小鼠中,所研究的5种核糖核酸酶的血浆清除率相似:人胰腺核糖核酸酶、血管生成素、嗜酸性粒细胞衍生神经毒素、癌酶和牛精浆核糖核酸酶。平均清除率为0.13 ml/min,即肾小球滤过率的60%(通过腹腔植入渗透泵持续输注期间用[14C]菊粉清除率测定)。与其他核糖核酸酶相比,血管生成素具有更高的分布容积和血浆至肌肉的转运速率,提示其与内皮细胞结合。这些核糖核酸酶在器官分布上有显著差异。对肿瘤细胞毒性最大的核糖核酸酶癌酶,在肾脏中的保留时间最长:在180分钟时,50%的注射剂量存在于肾脏中,而其他核糖核酸酶在肾脏中的保留量仅为1%或更少。癌酶从肾脏清除较慢可能是由于其在肾脏中的结合程度较高或对蛋白水解降解有抗性。为了阐明参与组织摄取的分子决定因素,我们研究了重组癌酶和两种癌酶 - 胰腺核糖核酸酶嵌合蛋白的生物分布。癌酶的组织保留特性似乎至少位于两个区域,其中一个区域在氨基末端的9个氨基酸α螺旋中。癌酶的氨基末端焦谷氨酸,是核糖核酸酶活性和细胞毒性所必需的残基,在肾脏保留中不起作用。